Ajanta Non Current Assets Total from 2010 to 2024

AJANTPHARM   3,027  30.05  1.00%   
Ajanta Pharma's Non Current Assets Total are increasing with slightly volatile movements from year to year. Non Current Assets Total are estimated to finish at about 20 B this year. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
2014-06-30
Previous Quarter
-4.6 B
Current Value
20 B
Quarterly Volatility
9.6 B
 
Yuan Drop
 
Covid
Check Ajanta Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ajanta Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 83.5 M or Selling And Marketing Expenses of 42.7 M, as well as many indicators such as . Ajanta financial statements analysis is a perfect complement when working with Ajanta Pharma Valuation or Volatility modules.
  
This module can also supplement various Ajanta Pharma Technical models . Check out the analysis of Ajanta Pharma Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Ajanta Stock

Ajanta Pharma financial ratios help investors to determine whether Ajanta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ajanta with respect to the benefits of owning Ajanta Pharma security.